🇺🇸 FDA
Patent

US 11397184

Selection of patients for combination therapy

granted A61KA61K31/4406A61K31/5685

Quick answer

US patent 11397184 (Selection of patients for combination therapy) held by Syndax Pharmaceuticals, Inc. expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Syndax Pharmaceuticals, Inc.
Grant date
Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4406, A61K31/5685, A61K39/3955, A61K45/06